[toc]

- [Summaries](#summaries)
  - [Table 1: Virus Variants and Spike Mutations vs Monoclonal Antibodies](#table.1.virus.variants.and.spike.mutations.vs.monoclonal.antibodies)
  - [Table 2: Virus Variants and Spike Mutations vs Convalescent Plasma](#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma.and.plasma.from.vaccinated.persons)
  - [Table 3: Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons](#table.3.virus.variants.and.spike.mutations.vs.plasma.from.vaccinated.persons)
  - [Figure: Virus Variants and Spike Mutations vs Convalescent Plasma and Plasma from Vaccinated Persons](/page/susceptibility-data/figure/#figure.virus.variants.and.spike.mutations.vs.convalescent.plasma.and.plasma.from.vaccinated.persons)
- Raw data
  - [Spike variants and mutation combinations / monoclonal antibodies neutralization](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-variants-and-mutation-combinations-mab-neutralization)
  - [Spike variants and mutation combinations / plasma neutralization](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-variants-and-mutation-combinations-plasma-neutralization)
  - [Spike mutations _in vitro_ selection](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-mutation-invitro-selection)
  - [Spike mutations _in vivo_ selection](https://hivdb.github.io/covid-drdb-reports/resistance-dt.html#spike-mutation-invivo-selection)
- Individual study details
  - [Table S1: Neutralizing Sensitivity of Variants to Monoclonal Antibodies](/page/susceptibility-data/mab-variants/)
  - [Table S2: Neutralizing Sensitivity of Spike Mutations to Monoclonal Antibodies](/page/susceptibility-data/mab-mutations/)
  - [Table S3: Neutralizing Sensitivity of Variants to Convalescent Plasma](/page/susceptibility-data/cp-variants/)
  - [Table S4: Neutralizing Sensitivity of Spike Mutations to Convalescent Plasma](/page/susceptibility-data/cp-mutations/)
  - [Table S5: Neutralizing Sensitivity of Variants to Plasma from Vaccinated Persons](/page/susceptibility-data/vp-variants/)
  - [Table S6: Neutralizing Sensitivity of Spike Mutations to Plasma from Vaccinated Persons](/page/susceptibility-data/vp-mutations/)
- [References](#references)

[/toc]

## Summaries

### Table 1: Virus Variants and Spike Mutations vs Monoclonal Antibodies

Fold reduced neutralizing susceptibility to monoclonal antibodies under Emergency Use Authorization(EUA)

[table compact, lastCompact]
table_mab
[/table]

Fold reduced neutralizing susceptibility to monoclonal antibodies in other clinical trials

[table compact,lastCompact]
table_mab_non_eua
[/table]

- The fold change is the median value of samples, the subscript is the number of samples. “-“ indicates absence of susceptibility data. “\*“ indicates conflict between two research groups, with one showing high-level of reduced susceptibility especially using IC80 rather than IC50.
- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.526**: L5F, T95I, D253G, E484K, D614G, A701V. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G.
- Monoclonal antibody(mAb) abbreviations: **BAM**: Bamlanivimab/LY-CoV555, **CAS**: Casirivimab/REGN10933, **IMD**: Imdevimab/REGN10987, **CAS/IMD**: Casirivimab+imdevimab/REGN-COV2, **ETE**: Etesevimab/LY-CoV016/JS016/CB6, **CIL**: Cilgavimab/COV2-2130/AZD1061, **TIX**: Tixagevimab/COV2-2196/AZD8895, **TIX/CIL**: Tixagevimab+Cilgavimab, **BAM/ETE**: Bamlanivimab+Etesevimab, **SOT**: Sotrovimab/Vir-7831/S309, **REG**: Regdanvimab/CT-P59.
- The color scheme indicates the fold-reduction in neutralization: <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span> – &lt;3-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span> – 3 to 9.9-fold reduced susceptibility; <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span> – ≥10-fold reduced susceptibility.



### Table 2: Virus Variants and Spike Mutations vs Convalescent Plasma

[table compact,lastCompact]
table_cp
[/table]

- Convalescent plasma in all studies is presumed likely to have been obtained from persons infected with spike variants lacking mutations associated with reduced neutralization susceptibility.
- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G.

### Table 3: Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons

[table compact,lastCompact]
table_vp
[/table]

- **B.1.1.7**: ∆69/70, ∆144, N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. **B.1.351**: L18F, D80A, D215G, ∆242-244, R246I, K417N, E484K, N501Y, D614G, and A701V. **P.1**: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. **B.1.429/B.1.427**: S13I, W152C, L452R, D614G. **B.1.617**: G152D, E154K, L452R, E484Q, D614G, P681R, Q1071H.


<section>

<div class="figure-caption">

## References

- **Alenquer21**: [^Alenquer21#inline]
- **Andreano20b**: [^Andreano20b#inline]
- **Bates21**: [^Bates21#inline]
- **Baum20**: [^Baum20#inline]
- **Becker21**: [^Becker21#inline]
- **Betton21**: [^Betton21#inline]
- **Brown21**: [^Brown21#inline]
- **Cathcart21**: [^Cathcart21#inline]
- **Cele21**: [^Cele21#inline]
- **Chen21**: [^Chen21#inline]
- **Collier21**: [^Collier21#inline]
- **Copin21**: [^Copin21#inline]
- **Dejnirattisai21**: [^Dejnirattisai21#inline]
- **Deng21**: [^Deng21#inline]
- **Dong21**: [^Dong21#inline]
- **Du20**: [^Du20#inline]
- **Edara21**: [^Edara21#inline]
- **Edara21b**: [^Edara21b#inline]
- **Edara21c**: [^Edara21c#inline]
- **Emary21**: [^Emary21#inline]
- **FDA21**: [^FDA21#inline]
- **Faulkner21**: [^Faulkner21#inline]
- **Ferreira21**: [^Ferreira21#inline]
- **Garcia-Beltran21**: [^Garcia-Beltran21#inline]
- **Goel21**: [^Goel21#inline]
- **Gottlieb21**: [^Gottlieb21#inline]
- **Greaney20**: [^Greaney20#inline]
- **Greaney21**: [^Greaney21#inline]
- **Greaney21c**: [^Greaney21c#inline]
- **Gu21**: [^Gu21#inline]
- **Hoffmann21**: [^Hoffmann21#inline]
- **Hoffmann21b**: [^Hoffmann21b#inline]
- **Hoffmann21c**: [^Hoffmann21c#inline]
- **Hu21**: [^Hu21#inline]
- **Huang21b**: [^Huang21b#inline]
- **Ikegame21**: [^Ikegame21#inline]
- **Jangra21**: [^Jangra21#inline]
- **Kemp21**: [^Kemp21#inline]
- **Kuzmina21**: [^Kuzmina21#inline]
- **Lee21**: [^Lee21#inline]
- **Leier21**: [^Leier21#inline]
- **Li20h**: [^Li20h#inline]
- **Li21c**: [^Li21c#inline]
- **Li21d**: [^Li21d#inline]
- **Lien21**: [^Lien21#inline]
- **Liu21**: [^Liu21#inline]
- **Liu21b**: [^Liu21b#inline]
- **Madhi21**: [^Madhi21#inline]
- **Mallm21**: [^Mallm21#inline]
- **Marot21**: [^Marot21#inline]
- **McCallum21**: [^McCallum21#inline]
- **McCallum21b**: [^McCallum21b#inline]
- **Monin-Aldama21**: [^Monin-Aldama21#inline]
- **Moyo-Gwete21**: [^Moyo-Gwete21#inline]
- **Muik21**: [^Muik21#inline]
- **Planas21**: [^Planas21#inline]
- **Rees-Spear21**: [^Rees-Spear21#inline]
- **Rondinone21**: [^Rondinone21#inline]
- **Rothenberger21**: [^Rothenberger21#inline]
- **Sahin20**: [^Sahin20#inline]
- **Sapkal21**: [^Sapkal21#inline]
- **Sapkal21b**: [^Sapkal21b#inline]
- **Shen21**: [^Shen21#inline]
- **Shen21b**: [^Shen21b#inline]
- **Skelly21**: [^Skelly21#inline]
- **Stamatatos21**: [^Stamatatos21#inline]
- **Stankov21**: [^Stankov21#inline]
- **Starr21**: [^Starr21#inline]
- **Supasa21**: [^Supasa21#inline]
- **Tada21**: [^Tada21#inline]
- **Tada21b**: [^Tada21b#inline]
- **Tang21**: [^Tang21#inline]
- **Tortorici20**: [^Tortorici20#inline]
- **Trinite21**: [^Trinite21#inline]
- **Vanhove21**: [^Vanhove21#inline]
- **Virtanen21**: [^Virtanen21#inline]
- **Wang21**: [^Wang21#inline]
- **Wang21b**: [^Wang21b#inline]
- **Wang21d**: [^Wang21d#inline]
- **Wang21e**: [^Wang21e#inline]
- **Wang21f**: [^Wang21f#inline]
- **Wang21g**: [^Wang21g#inline]
- **Weigang21**: [^Weigang21#inline]
- **Weisblum20**: [^Weisblum20#inline]
- **West21**: [^West21#inline]
- **Westendorf21**: [^Westendorf21#inline]
- **Wibmer21**: [^Wibmer21#inline]
- **Widera21**: [^Widera21#inline]
- **Wu21**: [^Wu21#inline]
- **Wu21b**: [^Wu21b#inline]
- **Xie21**: [^Xie21#inline]
- **Xie21b**: [^Xie21b#inline]
- **Yadav21**: [^Yadav21#inline]
- **Yao21**: [^Yao21#inline]
- **Yuan21**: [^Yuan21#inline]
- **Zhou21b**: [^Zhou21b#inline]
- **Zhou21c**: [^Zhou21c#inline]
- **Zuckerman21**: [^Zuckerman21#inline]
- **deSouza21**: [^deSouza21#inline]

</div>

</section>
